Literature DB >> 8962138

Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display.

I A Lorimer1, A Keppler-Hafkemeyer, R A Beers, C N Pegram, D D Bigner, I Pastan.   

Abstract

EGFRvIII is a mutant epidermal growth factor receptor found in glioblastoma, and in carcinoma of the breast, ovary, and lung. The mutant receptor has a deletion in its extracellular domain that results in the formation of a new, tumor-specific extracellular sequence. Mice were immunized with a synthetic peptide corresponding to this sequence and purified EGFRvIII. A single chain antibody variable domain (scFv) phage display library of 8 x 10(6) members was made from the spleen of one immunized mouse. A scFv specific for EGFRvIII was isolated from this library by panning with successively decreasing amounts of synthetic peptide. This was used to make an immunotoxin by fusing the scFv DNA sequence to sequences coding for domains II and III of Pseudomonas exotoxin A. Purified immunotoxin had a Kd of 22 nM for peptide and a Kd of 11 nM for cell-surface EGFRvIII. The immunotoxin was very cytotoxic to cells expressing EGFRvIII, with an IC50 of 1 ng/ml (16 pM) on mouse fibroblasts transfected with EGFRvIII and an IC50 of 7-10 ng/ml (110-160 pM) on transfected glioblastoma cells. There was no cytotoxic activity at 1000 ng/ml on the untransfected parent glioblastoma cell line. The immunotoxin was completely stable upon incubation at 37 degrees C for 24 h in human serum. The combination of good affinity, cytotoxicity and stability make this immunotoxin a candidate for further preclinical evaluation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8962138      PMCID: PMC26219          DOI: 10.1073/pnas.93.25.14815

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas.

Authors:  N Sugawa; A J Ekstrand; C D James; V P Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

2.  Single-chain antigen-binding proteins.

Authors:  R E Bird; K D Hardman; J W Jacobson; S Johnson; B M Kaufman; S M Lee; T Lee; S H Pope; G S Riordan; M Whitlow
Journal:  Science       Date:  1988-10-21       Impact factor: 47.728

3.  Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.

Authors:  J S Huston; D Levinson; M Mudgett-Hunter; M S Tai; J Novotný; M N Margolies; R J Ridge; R E Bruccoleri; E Haber; R Crea
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

4.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

Authors:  T A Libermann; H R Nusbaum; N Razon; R Kris; I Lax; H Soreq; N Whittle; M D Waterfield; A Ullrich; J Schlessinger
Journal:  Nature       Date:  1985 Jan 10-18       Impact factor: 49.962

5.  Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.

Authors:  P A Humphrey; A J Wong; B Vogelstein; M R Zalutsky; G N Fuller; G E Archer; H S Friedman; M M Kwatra; S H Bigner; D D Bigner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

6.  A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin.

Authors:  V K Chaudhary; C Queen; R P Junghans; T A Waldmann; D J FitzGerald; I Pastan
Journal:  Nature       Date:  1989-06-01       Impact factor: 49.962

7.  Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library.

Authors:  T J Vaughan; A J Williams; K Pritchard; J K Osbourn; A R Pope; J C Earnshaw; J McCafferty; R A Hodits; J Wilton; K S Johnson
Journal:  Nat Biotechnol       Date:  1996-03       Impact factor: 54.908

8.  A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors.

Authors:  H Yamazaki; Y Ohba; N Tamaoki; M Shibuya
Journal:  Jpn J Cancer Res       Date:  1990-08

9.  B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice.

Authors:  U Brinkmann; L H Pai; D J FitzGerald; M Willingham; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 12.779

10.  Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL.

Authors:  S Seetharam; V K Chaudhary; D FitzGerald; I Pastan
Journal:  J Biol Chem       Date:  1991-09-15       Impact factor: 5.486

View more
  30 in total

1.  A TVA-single-chain antibody fusion protein mediates specific targeting of a subgroup A avian leukosis virus vector to cells expressing a tumor-specific form of epidermal growth factor receptor.

Authors:  S Snitkovsky; T M Niederman; B S Carter; R C Mulligan; J A Young
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

Review 2.  Therapeutic inhibition of angiogenesis.

Authors:  Hua-Tang Zhang; Roy Bicknell
Journal:  Mol Biotechnol       Date:  2003-10       Impact factor: 2.695

Review 3.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

4.  An entirely cell-based system to generate single-chain antibodies against cell surface receptors.

Authors:  Barbara D Lipes; Yu-Hsun Chen; Hongzheng Ma; Herman F Staats; Daniel J Kenan; Michael Dee Gunn
Journal:  J Mol Biol       Date:  2008-04-07       Impact factor: 5.469

5.  Competitive selection from single domain antibody libraries allows isolation of high-affinity antihapten antibodies that are not favored in the llama immune response.

Authors:  Sofia Tabares-da Rosa; Martin Rossotti; Carmen Carleiza; Federico Carrión; Otto Pritsch; Ki Chang Ahn; Jerold A Last; Bruce D Hammock; Gualberto González-Sapienza
Journal:  Anal Chem       Date:  2011-08-29       Impact factor: 6.986

6.  Engineering toxin-resistant therapeutic stem cells to treat brain tumors.

Authors:  Daniel W Stuckey; Shawn D Hingtgen; Nihal Karakas; Benjamin E Rich; Khalid Shah
Journal:  Stem Cells       Date:  2015-02       Impact factor: 6.277

7.  An artificial cell-cycle inhibitor isolated from a combinatorial library.

Authors:  B A Cohen; P Colas; R Brent
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

8.  Nanobody-based binding assay for the discovery of potent inhibitors of CFTR inhibitory factor (Cif).

Authors:  Natalia Vasylieva; Seiya Kitamura; Jiexian Dong; Bogdan Barnych; Kelli L Hvorecny; Dean R Madden; Shirley J Gee; Dennis W Wolan; Christophe Morisseau; Bruce D Hammock
Journal:  Anal Chim Acta       Date:  2019-01-09       Impact factor: 6.558

9.  Genetic modification of mesenchymal stem cells to express a single-chain antibody against EGFRvIII on the cell surface.

Authors:  Irina V Balyasnikova; Rosa Franco-Gou; J Michael Mathis; Maciej S Lesniak
Journal:  J Tissue Eng Regen Med       Date:  2010-06       Impact factor: 3.963

10.  Genetically engineered T cells to target EGFRvIII expressing glioblastoma.

Authors:  Szofia S Bullain; Ayguen Sahin; Oszkar Szentirmai; Carlos Sanchez; Ning Lin; Elizabeth Baratta; Peter Waterman; Ralph Weissleder; Richard C Mulligan; Bob S Carter
Journal:  J Neurooncol       Date:  2009-04-23       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.